Compositions and methods related to anti-CD19 antibody drug conjugates

Abstract The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD 19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD 19, as well as methods of making and using tltese anti-CD 19 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.